In Segment C, individuals will acquire ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Members will get treatment right up until sickness progression or the participants are unable to tolerate the study drugs. Ubiquitin-connected proteins that regulate The steadiness of key Tremendous enhancer-mediated proteins have https://abbv-744-safety-and-side13568.eedblog.com/32140389/detailed-notes-on-abbv-744-brd4-inhibitor-mechanism-of-action